Form 4 for RANI Rani Therapeutics Holdings, Inc.
Accepted 2023-12-08 00:00:00 ET · period of report 2023-11-24 · accession 0001104659-23-124723 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-12-08 | 2023-11-24 | RANI | Aequanimitas Limited Partnership | 10% | S - Sale | $2.01 | -5.27M | 8,400 | -100% | -$10.58M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-24 | S | D | 5,265,165 | $2.01 | 8,400 | I Shares indirectly held through Aequanimitas Limited Partnership | — | — | (F2) Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas. |